Continuous manufacturing outperforms fed-batch processes by offering uninterrupted processing from cell culture to the final drug substance. It maximizes resource efficiency, achieving a remarkable 10-fold increase in upstream productivity and a 25-50% improvement in downstream, while eliminating multiple hold steps and transfers of in process material. This approach enhances product quality through degradation minimization, enables reduction in emissions, and provides flexible design options for cost-effective manufacturing. Costs per gram can be slashed by up to 40%, making it a highly attractive option for biologics production.